Talecris Biotherapeutics' top executive has been tight-lipped since June, when the company announced its $4 billion buyout by Grifols of Spain.
This morning, the company reported stronger quarterly earnings but CEO Larry Stern once again didn't hold a conference call with Wall Street analysts. He hasn't publicly commented on the progress of the deal, or much else.
But in an internal employee newsletter this month, Stern emphasizes that the company is continuing its work producing medicine from blood plasma, regardless of the merger with Grifols.
He also raises the possibility that the deal might not happen.
"Whether U.S. and global regulatory authorities approve the merger with Grifols, or we are once again left standing at the altar, I'm confident we have the strategies, plans and entrepreneurial team to embrace change and actively shape our destiny," Stern wrote.